8-K: Acrivon Therapeutics Announces Positive ACR-368 Data in Endometrial Cancer and Provides Financial Update

Acrivon Therapeutics reports promising clinical data for ACR-368 in endometrial cancer patients and extends its cash runway into 2027.

Summary

• Acrivon Therapeutics announced its fourth quarter and full year 2024 financial results and provided program updates.
• The company's AP3 platform is designed for streamlined drug discovery.
• ACR-368 showed a 35% confirmed overall response rate (cORR) in OncoSignature-positive (BM+) endometrial cancer patients who had progressed on prior anti-PD-1 and chemotherapy, which is more than double the response rate of their last prior line of therapy (15%).
• In BM+ patients who relapsed after prior anti-PD-1 and chemotherapy, the cORR was 50% with a median duration of response (mDOR) not yet reached (>10 months).
• In BM+ patients refractory to their last prior line of therapy, the cORR was 33% and mDoR was approximately 3.4 months.
• Endometrial cancer is prioritized due to limited treatment options and commercial opportunity.
• The Phase 1 trial of ACR-2316 is ahead of schedule, with enrollment in the first three dose-escalation cohorts completed and initial clinical activity observed.
• The company's cash runway is extended into 2027.
• Net loss for the quarter ended December 31, 2024 was $22.8 million, and $80.6 million for the full year.
• Research and development expenses were $18.6 million for the quarter and $64.0 million for the full year.
• As of December 31, 2024, the company had cash, cash equivalents, and investments of $184.6 million.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and a strong cash position, indicating a favorable outlook for the company. However, the increased net loss and deprioritization of certain programs temper the overall sentiment.

Positives

• ACR-368 shows promising clinical activity in heavily pretreated endometrial cancer patients.
• The ACR-368 OncoSignature assay accurately identified patients whose tumors are sensitive to ACR-368, with 80% of BM+ patients demonstrating tumor shrinkage.
• Phase 1 trial of ACR-2316 is progressing ahead of schedule with initial clinical activity observed.
• The company has a strong cash position, providing a runway into 2027.
• The FDA has granted Breakthrough Device designations for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
• Fast Track designation from the FDA for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer.

Negatives

• The company reported a net loss of $80.6 million for the full year 2024, which is higher than the $60.4 million loss in 2023.
• Ovarian cancer is being deprioritized due to increased competition and a smaller market opportunity.
• Bladder cancer is also being deprioritized due to lower than preclinically predicted BM+ rate, leading to enrollment challenges.

Risks

• The ACR-368 OncoSignature test has not yet obtained regulatory approval.
• The company's forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
• The company's future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements and are subject to change.

Future Outlook

The company anticipates providing an update on the registrational intent trial and confirmatory trial design for ACR-368, reporting initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025, and advancing a new potential first-in-class cell cycle drug discovery program towards development candidate nomination in 2025.

Management Comments

• We continue executing our highly differentiated Generative Phosphoproteomics AP3-enabled strategy, delivering rapid progress towards key milestones across all programs, including our clinical assets, ACR-368 and ACR-2316, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
• We previously identified endometrial cancer as a sensitive tumor type with our AP3 platform prior to clinical entry.
• Despite patients presenting with large, heavily pretreated tumors (including 65% treated with prior pembrolizumab and lenvatinib) with aggressive histopathologies (75% serous or carcinosarcomas), pMMR, and p53 mutations, we observed strong anti-tumor activity, both among refractory and relapsed patients.

Industry Context

Acrivon's focus on precision medicine and the use of its AP3 platform to identify patients most likely to respond to its therapies aligns with the growing trend in oncology towards personalized treatment approaches. The prioritization of endometrial cancer reflects the unmet need for effective therapies in this area, where current treatment options are limited.

Comparison to Industry Standards

• The reported 35% cORR for ACR-368 in BM+ endometrial cancer patients is significantly higher than the standard of care ORR of 10-12% for second-line therapy, based on estimates from key opinion leaders and derived from control arms of past Phase 2 trials.
• The 50% cORR in patients that had relapsed after the prior line of therapy is also a notable improvement compared to existing treatments.
• Companies like Relay Therapeutics and Black Diamond Therapeutics are also focused on precision oncology, but Acrivon's AP3 platform offers a unique approach to drug discovery and patient selection.

Stakeholder Impact

• Shareholders: Positive clinical data and extended cash runway are likely to be viewed favorably.
• Employees: Prioritization of endometrial cancer program and advancement of ACR-2316 may provide job security and growth opportunities.
• Patients: Promising clinical data for ACR-368 offers hope for improved treatment options in endometrial cancer.
• Creditors: Strong cash position reduces the risk of default.

Next Steps

• Provide update on registrational intent trial and confirmatory trial design for ACR-368.
• Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025.
• Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025.

Key Dates

Keywords

Acrivon Therapeutics, ACR-368, ACR-2316, endometrial cancer, AP3 platform, precision medicine, OncoSignature, clinical trial, financial results, CHK1, CHK2, WEE1, PKMYT1